Sector News

UCB spins out neuro startup with €17M from Novo, Johnson & Johnson

February 8, 2018
Life sciences

UCB has licensed a small molecule program for cognitive disorders to Syndesi Therapeutics, which launched Thursday with a €17 million ($20.9 million) investment from the likes of V-Bio Ventures and the venture arms of Novo Nordisk and Johnson & Johnson.

Syndesi has an exclusive license from UCB to develop and commercialize a group of molecules that modulate the synaptic vesicle protein SV2A, which is involved in transmitting impulses between neurons in the brain.

The startup will look into the potential of these molecules in the treatment of Alzheimer’s disease, as well as other dementias and schizophrenia-linked cognitive impairment.

“Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of Alzheimer’s Disease and other indications characterized by cognitive impairment,” said Jonathan Savidge, Syndesi CEO, in the statement. “Syndesi benefits both from UCB’s research expertise and from an impressive syndicate of experienced investors and their respective networks.”

The series A round, led by Novo Seeds and Fountain Healthcare, will support the clinical development of the lead candidate up to early proof of concept in humans.

Syndesi is based at the Centre d’Entreprises et d’Innovation in Louvain-la-Neuve, Belgium, and has space at Johnson & Johnson’s JLINX incubator in Beerse. But the incubator is getting a makeover—launched in March 2016 as a collaboration between Janssen and Bioqube Ventures, JLINX will transition into a JLABS site, the first such site in Europe.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).